Loading…
Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital
Background: Methicillin-resistant Staphylococcus aureus (MRSA) is an organism causing significant mortality and morbidity with nosocomial infections. Ceftaroline is a new cephalosporin antibiotic that has activity against MRSA. In the USA, this antibiotic has not been approved for use in pneumonia c...
Saved in:
Published in: | Journal of community hospital internal medicine perspectives 2017-01, Vol.7 (5), p.300-302 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background: Methicillin-resistant Staphylococcus aureus (MRSA) is an organism causing significant mortality and morbidity with nosocomial infections. Ceftaroline is a new cephalosporin antibiotic that has activity against MRSA. In the USA, this antibiotic has not been approved for use in pneumonia caused by MRSA.
Objectives: To review the use of ceftaroline in MRSA pneumonia in a US hospital and evaluate its clinical success.
Methods: A retrospective study was conducted in an urban community hospital assessing the use of ceftaroline for MRSA pneumonia.
Results: The clinical success was comparable to the currently approved treatment for MRSA pneumonia.
Conclusion: The results of our study showed a favorable result for the treatment of MRSA pneumonia. Well-designed studies need to be performed for further validation of these results. |
---|---|
ISSN: | 2000-9666 2000-9666 |
DOI: | 10.1080/20009666.2017.1374107 |